Infections and CAR-T cells for the treatment of lymphoid malignancies: a narrative review - Takeaways - MDSpire

Infections and CAR-T cells for the treatment of lymphoid malignancies: a narrative review

  • By

  • Carolina Secreto

  • Filippo Fasano

  • Davide Stella

  • Mattia Novo

  • Barbara Botto

  • Marco Cerrano

  • Roberto Freilone

  • Alessandro Busca

  • June 16, 2026

  • 0 min

Share

  • 1

    CAR-T cell therapy has transformed treatment for lymphoid malignancies but is associated with significant infectious complications.

  • 2

    Infections after CAR-T therapy follow a biphasic pattern, with early infections occurring within the first 30 days and late infections thereafter.

  • 3

    Bacterial infections are most common in the early phase, while viral and opportunistic infections become more prevalent in the long-term.

  • 4

    Risk factors for infections include host-related factors like underlying malignancy and treatment-related factors such as CRS and hypogammaglobulinemia.

  • 5

    Infections are a leading cause of non-relapse mortality in CAR-T patients, highlighting the need for vigilant monitoring and management.

Original Source(s)

Infections and CAR-T cells for the treatment of lymphoid malignancies: a narrative review

  • by Carolina Secreto, Filippo Fasano, Davide Stella, Mattia Novo, Barbara Botto, Marco Cerrano, Roberto Freilone, Alessandro Busca

  • June 16, 2026

Related Content

Case Report: ETV6 c.744del gene mutation acute lymphoblastic leukemia in identical twins

Access to Specialty Cancer Care and Plan Disenrollment Among Medicare Beneficiaries

Narrow Networks and Coverage Changes Among Medicare Advantage Beneficiaries With Cancer